Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agenus (AGEN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (41)	10/12/2005 1:45:54 PM
From: DewDiligence_on_SI	Respond to of 146

[OT] Though some don't like Dew's links on SI… Perhaps some people on clubby SI think iHub is a competing site, not realizing that SI is actually owned by iHub. By the way, your point about the vanishing newswire links on Yahoo Finance is a good one—in my experience these links disappear after about three months. A lot of the original newswires are posted on iHub, so you can check there if you can’t find what you want here. Regards, Dew

To: tuck who wrote (41)	10/13/2005 10:08:21 AM
From: rkrw	Read Replies (1) \| Respond to of 146

<<<Next point of any major interest would be an interim look at pivotal trial data. That will be a over a year.>>> Trial to watch is renal cell, 800 patient pivotal, data should be out in just a few months. Press Release Source: Antigenics Inc. Antigenics Appoints Jill M. Forrest as Vice President of Marketing and Sales Thursday October 13, 7:00 am ET NEW YORK--(BUSINESS WIRE)--Oct. 13, 2005--Antigenics Inc. (NASDAQ: AGEN - News) today announced that Jill M. Forrest has been appointed to the newly created position of vice president of marketing and sales. In this role, Ms. Forrest will be responsible for leading all precommercial and commercialization activities in preparation for the launch of Oncophage® (vitespen; formerly HSPPC-96) and other late-stage product candidates. "With encouraging data from our Phase 3 melanoma trial of Oncophage and our plans to build a commercial cancer presence expeditiously, it's an appropriate time for us to bring in a professional of exceptional attributes," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "Jill's experience in launching first-to-market oncology compounds as well as her extensive marketing and sales background in a broad range of oncology treatment settings will be invaluable to us as we prepare to build a commercial presence in oncology." Ms. Forrest brings to Antigenics 20 years of oncology expertise, including experience in clinical trials, sales, sales training and management, marketing and global product development. She was most recently director of global marketing at Bristol-Myers Squibb Oncology, where she was responsible for the premarketing and launch efforts for the novel oncology compound vinflunine. As a senior region business director, she played a key role in the launch of Erbitux(TM) (cetuximab), a targeted biological therapy for colorectal cancer, and led national sales performance for three consecutive years. As a director of marketing, she led the launch of the chemotherapy TAXOL® (paclitaxel) as an adjuvant treatment in breast cancer, as well as drove marketing efforts, resulting in a 40 percent increase in breast cancer sales. Ms. Forrest received a BA in psychology from the University of Kansas. About Antigenics